Researchers at Winship Cancer Institute Emory University report that a certain type of DNA market predicts poor outcomes in multiple myeloma. This marker, a kind of rearrangement of chromosomes rarely tested for, may indicate resistance to immunotherapy drugs such as lenalidomide which are now standard multiple myeloma standard therapies. The results have been published in Nature Communications. They are the result from the CoMMPass study.
Sagar LonialSource: Eurek Alert